Note 12 - Subsequent Events	12 Months Ended
Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note *12.* Subsequent events On January 9, 2024, the Company funded a $0.8 million equity investment to an existing portfolio company, Better Place Forests Co. Between January 18 and February 9, 2024, the Company made $0.9 million of new debt investments in Nexii Building Solutions, Inc., an existing portfolio company. On February 7, 2024, the Company funded a $14.0 million debt investment to an existing portfolio company, Ceribell, Inc. in connection with the prepayment of its existing $11.3 million debt investment. On February 20, 2024, HIMV LLC (“HIMV”) sold BioVaxys Technology Corp., a British Columbia-registered company (“Purchaser”), its intellectual property and related assets (“IP”) in consideration for (a) $750,000 in cash, (b) $250,000 in value of common shares of the Purchaser, at a price per share equal to the volume-weighted average price of the common shares in the capital of the Purchaser during the 20 trading day period immediately prior to the closing date of the sale and (c) certain other earn-out payments related to the development and use of the IP as set forth in the APA. The sale of the IP closed on February 20, 2024.

Note 12 - Subsequent Events

12 Months Ended

Dec. 31, 2023

Note 12. Subsequent events

On January 9, 2024, the Company funded a $0.8 million equity investment to an existing portfolio company, Better Place Forests Co.

Between January 18 and February 9, 2024, the Company made $0.9 million of new debt investments in Nexii Building Solutions, Inc., an existing portfolio company.

On February 7, 2024, the Company funded a $14.0 million debt investment to an existing portfolio company, Ceribell, Inc. in connection with the prepayment of its existing $11.3 million debt investment.

On February 20, 2024, HIMV LLC (“HIMV”) sold BioVaxys Technology Corp., a British Columbia-registered company (“Purchaser”), its intellectual property and related assets (“IP”) in consideration for (a) $750,000 in cash, (b) $250,000 in value of common shares of the Purchaser, at a price per share equal to the volume-weighted average price of the common shares in the capital of the Purchaser during the 20 trading day period immediately prior to the closing date of the sale and (c) certain other earn-out payments related to the development and use of the IP as set forth in the APA. The sale of the IP closed on February 20, 2024.